Brian P. Hobbs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Brian P. Hobbs has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Steven Hsesheng Lin
The University of Texas MD Anderson Cancer Center
5 shared publications - Alexander M. Kaizer
Department of Biostatistics and Informatics, School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, USA
4 shared publications - Alok A. Khorana
Department of Hematology-Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2 shared publications - Brian I. Rini
Vanderbilt Ingram Cancer Center, Nashville, TN, USA
2 shared publications Chaan S. Ng
Department of Diagnostic Radiology , Houston , TX , USA
2 shared publications- Chaan S. Ng
Department of Radiology, University of Texas M.D. Anderson Cancer Center, Houston, TX
2 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (3)
Bayesian Multistate Transition Modeling of Response, Progression, and Death to Elucidate Mechanisms of Survival Benefit in Oncology Trials
PURPOSE: Innovate a novel Bayesian nonparametric approach for clinical trial analysis devised to infer intrinsic survival benefit mechanisms of action (SBMoA) in confirmatory randomized controlled trials (RCTs) with survival end point by comparing 12 intrinsic state transitions between stable disease, early response, progression/recurrence, and death. METHODS: The method characterizes patient trajectories through states of stable disease, response, progression, and death using multiplicative transition intensities. Bayesian inference compares observed transition rate differences with benchmark distributions for five SBMoAs (Null, Survival Null, Mediation, Direct, Mixed), yielding posterior predictive probabilities. Performance was evaluated via simulations of phase III trials implemented to compare the accuracy of 12-month interim analyses with final survival analysis results, as well as to compare these results with those obtained using Bayesian mediation modeling, 2-in-1 seamless designs, and group sequential designs for survival analysis. RESULTS: The accuracy of interim decision making in forecasting a trial's final outcome was highest for the SBMoA method (0.82), which outperformed conditional power (0.65), Pocock (0.60), Chen 2-in-1 (0.55), and O'Brien-Fleming (0.53). The method achieved positive predictive value (PPV) of 0.80 and negative predictive value (NPV) of 0.82, nearest to the ideal truth oracle (PPV 0.96, NPV 0.84) that assumes perfect knowledge of the true scenario. Comparators performed worse: conditional power (PPV 0.63, NPV 0.68), Pocock (PPV 0.72, NPV 0.58), Chen 2-in-1 (PPV 0.52, NPV 0.60), and O'Brien-Fleming (PPV 0.81, NPV 0.53). CONCLUSION: Inferring SBMoA using the Bayesian approach provides reliable interim forecasts of survival benefit in the absence of mature survival data. The innovation provides avenues for accelerating interim decision making with enhanced accuracy in confirmatory trials.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (3)
Open AccessBayesian Multistate Transition Modeling of Response, Progression, and Death to Elucidate Mechanisms of Survival Benefit in Oncology Trials
PURPOSE: Innovate a novel Bayesian nonparametric approach for clinical trial analysis devised to infer intrinsic survival benefit mechanisms of action (SBMoA) in confirmatory randomized controlled trials (RCTs) with survival end point by comparing 12 intrinsic state transitions between stable disease, early response, progression/recurrence, and death. METHODS: The method characterizes patient trajectories through states of stable disease, response, progression, and death using multiplicative transition intensities. Bayesian inference compares observed transition rate differences with benchmark distributions for five SBMoAs (Null, Survival Null, Mediation, Direct, Mixed), yielding posterior predictive probabilities. Performance was evaluated via simulations of phase III trials implemented to compare the accuracy of 12-month interim analyses with final survival analysis results, as well as to compare these results with those obtained using Bayesian mediation modeling, 2-in-1 seamless designs, and group sequential designs for survival analysis. RESULTS: The accuracy of interim decision making in forecasting a trial's final outcome was highest for the SBMoA method (0.82), which outperformed conditional power (0.65), Pocock (0.60), Chen 2-in-1 (0.55), and O'Brien-Fleming (0.53). The method achieved positive predictive value (PPV) of 0.80 and negative predictive value (NPV) of 0.82, nearest to the ideal truth oracle (PPV 0.96, NPV 0.84) that assumes perfect knowledge of the true scenario. Comparators performed worse: conditional power (PPV 0.63, NPV 0.68), Pocock (PPV 0.72, NPV 0.58), Chen 2-in-1 (PPV 0.52, NPV 0.60), and O'Brien-Fleming (PPV 0.81, NPV 0.53). CONCLUSION: Inferring SBMoA using the Bayesian approach provides reliable interim forecasts of survival benefit in the absence of mature survival data. The innovation provides avenues for accelerating interim decision making with enhanced accuracy in confirmatory trials.
- Open Access
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2500058
Bayesian Counterfactual Machine Learning Individualizes Radiation Modality Selection to Mitigate Immunosuppression
PURPOSE: Lymphocytes play critical roles in cancer immunity and tumor surveillance. Radiation-induced lymphopenia (RIL) is a common side effect observed in patients with cancer undergoing chemoradiation therapy (CRT), leading to impaired immunity and worse clinical outcomes. Although proton beam therapy (PBT) has been suggested to reduce RIL risk compared with intensity-modulated radiation therapy (IMRT), this study used Bayesian counterfactual machine learning to identify distinct patient profiles and inform personalized radiation modality choice. METHODS: A novel Bayesian causal inferential technique is introduced and applied to a matched retrospective cohort of 510 patients with esophageal cancer undergoing CRT to identify patient profiles for which immunosuppression could have been mitigated from radiation modality selection. RESULTS: BMI, age, baseline absolute lymphocyte count (ALC), and planning target volume determined the extent to which reductions in ALCs varied by radiation modality. Five patient profiles were identified. Significant variation in ALC nadir between PBT and IMRT was observed in three of the patient subtypes. Notably, older patients (age >69 years) with normal weight experienced a two-fold reduction in mean ALC nadir when treated with IMRT versus PBT. Mean ALC nadir was reduced significantly for IMRT patients with lower ALC at baseline (<1.6 k/µL) who were overweight or obese when compared with PBT, whereas overweight patients with higher baseline ALC showed clinical equipoise between modalities. CONCLUSION: Individualized radiation therapy selection can be an important tool to minimize immunosuppression for high-risk patients. The Bayesian counterfactual modeling techniques presented in this article are flexible enough to capture complex, nonlinear patterns while estimating interpretable patient profiles for translation into clinical protocols.
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2500058
Open AccessBayesian Counterfactual Machine Learning Individualizes Radiation Modality Selection to Mitigate Immunosuppression
PURPOSE: Lymphocytes play critical roles in cancer immunity and tumor surveillance. Radiation-induced lymphopenia (RIL) is a common side effect observed in patients with cancer undergoing chemoradiation therapy (CRT), leading to impaired immunity and worse clinical outcomes. Although proton beam therapy (PBT) has been suggested to reduce RIL risk compared with intensity-modulated radiation therapy (IMRT), this study used Bayesian counterfactual machine learning to identify distinct patient profiles and inform personalized radiation modality choice. METHODS: A novel Bayesian causal inferential technique is introduced and applied to a matched retrospective cohort of 510 patients with esophageal cancer undergoing CRT to identify patient profiles for which immunosuppression could have been mitigated from radiation modality selection. RESULTS: BMI, age, baseline absolute lymphocyte count (ALC), and planning target volume determined the extent to which reductions in ALCs varied by radiation modality. Five patient profiles were identified. Significant variation in ALC nadir between PBT and IMRT was observed in three of the patient subtypes. Notably, older patients (age >69 years) with normal weight experienced a two-fold reduction in mean ALC nadir when treated with IMRT versus PBT. Mean ALC nadir was reduced significantly for IMRT patients with lower ALC at baseline (<1.6 k/µL) who were overweight or obese when compared with PBT, whereas overweight patients with higher baseline ALC showed clinical equipoise between modalities. CONCLUSION: Individualized radiation therapy selection can be an important tool to minimize immunosuppression for high-risk patients. The Bayesian counterfactual modeling techniques presented in this article are flexible enough to capture complex, nonlinear patterns while estimating interpretable patient profiles for translation into clinical protocols.
- 23 January 2025
- Published by Oxford University Press (OUP) in Journal of the Royal Statistical Society Series C: Applied Statistics
- Vol. 74 (3) , 800-823
A patient similarity-embedded Bayesian approach to prognostic biomarker inference with application to thoracic cancer immunity
This paper introduces a novel statistical methodology integrating machine learning (ML) and Bayesian modelling to facilitate personalized prognostic predictions with application to oncology. Utilizing power priors, we construct ‘patient-similarity embeddings’ that identify localized patterns of prognosis. The methodology is applied to study the prognostic value of markers of anticancer immunity within the tumour microenvironment of nonsmall cell lung cancer while adjusting for established clinical characteristics. The method outperforms traditional regression and ML models, while accurately identifying subgroup patterns, thereby enhancing statistical inference and hypothesis testing.
- 23 January 2025
- Published by Oxford University Press (OUP) in Journal of the Royal Statistical Society Series C: Applied Statistics
- Vol. 74 (3) , 800-823
A patient similarity-embedded Bayesian approach to prognostic biomarker inference with application to thoracic cancer immunity
This paper introduces a novel statistical methodology integrating machine learning (ML) and Bayesian modelling to facilitate personalized prognostic predictions with application to oncology. Utilizing power priors, we construct ‘patient-similarity embeddings’ that identify localized patterns of prognosis. The methodology is applied to study the prognostic value of markers of anticancer immunity within the tumour microenvironment of nonsmall cell lung cancer while adjusting for established clinical characteristics. The method outperforms traditional regression and ML models, while accurately identifying subgroup patterns, thereby enhancing statistical inference and hypothesis testing.
- Open Access
- 1 July 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Machine learning identifies prognostic subtypes of the tumor microenvironment of NSCLC
The tumor microenvironment (TME) plays a fundamental role in tumorigenesis, tumor progression, and anti-cancer immunity potential of emerging cancer therapeutics. Understanding inter-patient TME heterogeneity, however, remains a challenge to efficient drug development. This article applies recent advances in machine learning (ML) for survival analysis to a retrospective study of NSCLC patients who received definitive surgical resection and immune pathology following surgery. ML methods are compared for their effectiveness in identifying prognostic subtypes. Six survival models, including Cox regression and five survival machine learning methods, were calibrated and applied to predict survival for NSCLC patients based on PD-L1 expression, CD3 expression, and ten baseline patient characteristics. Prognostic subregions of the biomarker space are delineated for each method using synthetic patient data augmentation and compared between models for overall survival concordance. A total of 423 NSCLC patients (46% female; median age [inter quantile range]: 67 [60–73]) treated with definite surgical resection were included in the study. And 219 (52%) patients experienced events during the observation period consisting of a maximum follow-up of 10 years and median follow up 78 months. The random survival forest (RSF) achieved the highest predictive accuracy, with a C-index of 0.84. The resultant biomarker subtypes demonstrate that patients with high PD-L1 expression combined with low CD3 counts experience higher risk of death within five-years of surgical resection.
- 1 July 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Open AccessMachine learning identifies prognostic subtypes of the tumor microenvironment of NSCLC
The tumor microenvironment (TME) plays a fundamental role in tumorigenesis, tumor progression, and anti-cancer immunity potential of emerging cancer therapeutics. Understanding inter-patient TME heterogeneity, however, remains a challenge to efficient drug development. This article applies recent advances in machine learning (ML) for survival analysis to a retrospective study of NSCLC patients who received definitive surgical resection and immune pathology following surgery. ML methods are compared for their effectiveness in identifying prognostic subtypes. Six survival models, including Cox regression and five survival machine learning methods, were calibrated and applied to predict survival for NSCLC patients based on PD-L1 expression, CD3 expression, and ten baseline patient characteristics. Prognostic subregions of the biomarker space are delineated for each method using synthetic patient data augmentation and compared between models for overall survival concordance. A total of 423 NSCLC patients (46% female; median age [inter quantile range]: 67 [60–73]) treated with definite surgical resection were included in the study. And 219 (52%) patients experienced events during the observation period consisting of a maximum follow-up of 10 years and median follow up 78 months. The random survival forest (RSF) achieved the highest predictive accuracy, with a C-index of 0.84. The resultant biomarker subtypes demonstrate that patients with high PD-L1 expression combined with low CD3 counts experience higher risk of death within five-years of surgical resection.
- Open Access
- 1 January 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 7 (7) , e2200294
Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non–Small-Cell Lung Cancer in the United States
PURPOSE: Many patients with actionable driver oncogenes (ADOs) are never identified and thus never receive targeted treatment. This study evaluated the economic impact and the potential life-years gained (LYG) that can be attributed to the extent of next-generation sequencing (NGS) testing in the United States compared with single-gene testing (SGT) in patients with metastatic nonsquamous non–small-cell lung cancer in the United States. METHODS: A model was developed to evaluate incremental rates of SGT or NSG testing on the basis of LYG and cost per LYG. ADOs included for NGS included EGFR, ALK, ROS1, BRAF, RET, MET, and NTRK. SGT included EGFR and ALK. Assumptions were made for expected incidence of ADOs. Survival distributions were fit to published trial averages of median and 5-year overall survival. Treatment costs were estimated from drug cost averages. Reimbursement costs were based on data from the Center for Medicare and Medicaid Services. RESULTS: Each incremental 10% increase in NGS testing produces an average of 2,627.4 additional LYG, with an average cost savings per LYG of $75 US dollars (USD). Replacing SGT at the current rate of 80% with NGS testing would result in an average additional 21,09.6 LYG and reduce cost per LYG by an average of $599 USD. If 100% of eligible patients were tested with NGS and each identified patient had matched treatment, the total average cost per LYG would be $16,641.57 USD. CONCLUSION: On the basis of current evidence, population-level simulations demonstrate that clinically relevant gains in survival with non-negligible reduction in costs are obtainable from widespread adoption of NGS testing and appropriate treatment matching for patients with advanced nonsquamous non–small-cell lung cancer.
- 1 January 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 7 (7) , e2200294
Open AccessModeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non–Small-Cell Lung Cancer in the United States
PURPOSE: Many patients with actionable driver oncogenes (ADOs) are never identified and thus never receive targeted treatment. This study evaluated the economic impact and the potential life-years gained (LYG) that can be attributed to the extent of next-generation sequencing (NGS) testing in the United States compared with single-gene testing (SGT) in patients with metastatic nonsquamous non–small-cell lung cancer in the United States. METHODS: A model was developed to evaluate incremental rates of SGT or NSG testing on the basis of LYG and cost per LYG. ADOs included for NGS included EGFR, ALK, ROS1, BRAF, RET, MET, and NTRK. SGT included EGFR and ALK. Assumptions were made for expected incidence of ADOs. Survival distributions were fit to published trial averages of median and 5-year overall survival. Treatment costs were estimated from drug cost averages. Reimbursement costs were based on data from the Center for Medicare and Medicaid Services. RESULTS: Each incremental 10% increase in NGS testing produces an average of 2,627.4 additional LYG, with an average cost savings per LYG of $75 US dollars (USD). Replacing SGT at the current rate of 80% with NGS testing would result in an average additional 21,09.6 LYG and reduce cost per LYG by an average of $599 USD. If 100% of eligible patients were tested with NGS and each identified patient had matched treatment, the total average cost per LYG would be $16,641.57 USD. CONCLUSION: On the basis of current evidence, population-level simulations demonstrate that clinically relevant gains in survival with non-negligible reduction in costs are obtainable from widespread adoption of NGS testing and appropriate treatment matching for patients with advanced nonsquamous non–small-cell lung cancer.
- 20 October 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (30) , 3520-3528
Basket Trials: Review of Current Practice and Innovations for Future Trials
Advances in biology and immunology have elucidated genetic and immunologic origins of cancer. Innovations in sequencing technologies revealed that distinct cancer histologies shared common genetic and immune phenotypic traits. Pharmacologic developments made it possible to target these alterations, yielding novel classes of targeted agents whose therapeutic potential span multiple tumor types. Basket trials, one type of master protocol, emerged as a tool for evaluating biomarker-targeted therapies among multiple tumor histologies. Conventionally conducted within the phase II setting and designed to estimate high and durable objective responses, basket trials pose challenges to statistical design and interpretation of results. This article reviews basket trials implemented in oncology studies and discusses issues related to their statistical design and analysis.
- 20 October 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (30) , 3520-3528
Basket Trials: Review of Current Practice and Innovations for Future Trials
Advances in biology and immunology have elucidated genetic and immunologic origins of cancer. Innovations in sequencing technologies revealed that distinct cancer histologies shared common genetic and immune phenotypic traits. Pharmacologic developments made it possible to target these alterations, yielding novel classes of targeted agents whose therapeutic potential span multiple tumor types. Basket trials, one type of master protocol, emerged as a tool for evaluating biomarker-targeted therapies among multiple tumor histologies. Conventionally conducted within the phase II setting and designed to estimate high and durable objective responses, basket trials pose challenges to statistical design and interpretation of results. This article reviews basket trials implemented in oncology studies and discusses issues related to their statistical design and analysis.
- Open Access
- 20 September 2022
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 30
Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations
- 20 September 2022
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 30
Open AccessAugmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations
- Open Access
- 2 August 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (8) , e0272367
Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simon’s two-stage design and Bayesian predictive probability monitoring with information sharing across baskets
This article discusses and compares statistical designs of basket trial, from both frequentist and Bayesian perspectives. Baskets trials are used in oncology to study interventions that are developed to target a specific feature (often genetic alteration or immune phenotype) that is observed across multiple tissue types and/or tumor histologies. Patient heterogeneity has become pivotal to the development of non-cytotoxic treatment strategies. Treatment targets are often rare and exist among several histologies, making prospective clinical inquiry challenging for individual tumor types. More generally, basket trials are a type of master protocol often used for label expansion. Master protocol is used to refer to designs that accommodates multiple targets, multiple treatments, or both within one overarching protocol. For the purpose of making sequential decisions about treatment futility, Simon’s two-stage design is often embedded within master protocols. In basket trials, this frequentist design is often applied to independent evaluations of tumor histologies and/or indications. In the tumor agnostic setting, rarer indications may fail to reach the sample size needed for even the first evaluation for futility. With recent innovations in Bayesian methods, it is possible to evaluate for futility with smaller sample sizes, even for rarer indications. Novel Bayesian methodology for a sequential basket trial design based on predictive probability is introduced. The Bayesian predictive probability designs allow interim analyses with any desired frequency, including continual assessments after each patient observed. The sequential design is compared with and without Bayesian methods for sharing information among a collection of discrete, and potentially non-exchangeable tumor types. Bayesian designs are compared with Simon’s two-stage minimax design.
- 2 August 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (8) , e0272367
Open AccessBayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simon’s two-stage design and Bayesian predictive probability monitoring with information sharing across baskets
This article discusses and compares statistical designs of basket trial, from both frequentist and Bayesian perspectives. Baskets trials are used in oncology to study interventions that are developed to target a specific feature (often genetic alteration or immune phenotype) that is observed across multiple tissue types and/or tumor histologies. Patient heterogeneity has become pivotal to the development of non-cytotoxic treatment strategies. Treatment targets are often rare and exist among several histologies, making prospective clinical inquiry challenging for individual tumor types. More generally, basket trials are a type of master protocol often used for label expansion. Master protocol is used to refer to designs that accommodates multiple targets, multiple treatments, or both within one overarching protocol. For the purpose of making sequential decisions about treatment futility, Simon’s two-stage design is often embedded within master protocols. In basket trials, this frequentist design is often applied to independent evaluations of tumor histologies and/or indications. In the tumor agnostic setting, rarer indications may fail to reach the sample size needed for even the first evaluation for futility. With recent innovations in Bayesian methods, it is possible to evaluate for futility with smaller sample sizes, even for rarer indications. Novel Bayesian methodology for a sequential basket trial design based on predictive probability is introduced. The Bayesian predictive probability designs allow interim analyses with any desired frequency, including continual assessments after each patient observed. The sequential design is compared with and without Bayesian methods for sharing information among a collection of discrete, and potentially non-exchangeable tumor types. Bayesian designs are compared with Simon’s two-stage minimax design.
- 6 April 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 6 (6) , e2100390
Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts
PURPOSE: The customary approach to early-phase clinical trial design, where the focus is on identification of the maximum tolerated dose, is not always suitable for noncytotoxic or other targeted therapies. Many trials have continued to follow the 3 + 3 dose-escalation design, but with the addition of phase I dose-expansion cohorts to further characterize safety and assess efficacy. Dose-expansion cohorts are not always planned in advance nor rigorously designed. We introduce an approach to the design of phase I expansion cohorts on the basis of sequential predictive probability monitoring. METHODS: Two optimization criteria are proposed that allow investigators to stop for futility to preserve limited resources while maintaining traditional control of type I and type II errors. We demonstrate the use of these designs through simulation, and we elucidate their implementation with a redesign of the phase I expansion cohort for atezolizumab in metastatic urothelial carcinoma. RESULTS: A sequential predictive probability design outperforms Simon's two-stage designs and posterior probability monitoring with respect to both proposed optimization criteria. The Bayesian sequential predictive probability design yields increased power while significantly reducing the average sample size under the null hypothesis in the context of the case study, whereas the original study design yields too low type I error and power. The optimal efficiency design tended to have more desirable properties, subject to constraints on type I error and power, compared with the optimal accuracy design. CONCLUSION: The optimal efficiency design allows investigators to preserve limited financial resources and to maintain ethical standards by halting potentially large dose-expansion cohorts early in the absence of promising efficacy results, while maintaining traditional control of type I and II error rates.
- 6 April 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 6 (6) , e2100390
Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts
PURPOSE: The customary approach to early-phase clinical trial design, where the focus is on identification of the maximum tolerated dose, is not always suitable for noncytotoxic or other targeted therapies. Many trials have continued to follow the 3 + 3 dose-escalation design, but with the addition of phase I dose-expansion cohorts to further characterize safety and assess efficacy. Dose-expansion cohorts are not always planned in advance nor rigorously designed. We introduce an approach to the design of phase I expansion cohorts on the basis of sequential predictive probability monitoring. METHODS: Two optimization criteria are proposed that allow investigators to stop for futility to preserve limited resources while maintaining traditional control of type I and type II errors. We demonstrate the use of these designs through simulation, and we elucidate their implementation with a redesign of the phase I expansion cohort for atezolizumab in metastatic urothelial carcinoma. RESULTS: A sequential predictive probability design outperforms Simon's two-stage designs and posterior probability monitoring with respect to both proposed optimization criteria. The Bayesian sequential predictive probability design yields increased power while significantly reducing the average sample size under the null hypothesis in the context of the case study, whereas the original study design yields too low type I error and power. The optimal efficiency design tended to have more desirable properties, subject to constraints on type I error and power, compared with the optimal accuracy design. CONCLUSION: The optimal efficiency design allows investigators to preserve limited financial resources and to maintain ethical standards by halting potentially large dose-expansion cohorts early in the absence of promising efficacy results, while maintaining traditional control of type I and II error rates.
- Open Access
The Impact of Radiation Dose to Heart Substructures on Major Coronary Events and Patient Survival after Chemoradiation Therapy for Esophageal Cancer
Background: There is a paucity of data regarding the association between radiation exposure of heart substructures and the incidence of major coronary events (MCEs) in patients with esophageal cancer (ESOC) undergoing chemoradiation therapy. We studied radiation dosimetric determinants of MCE risk and measured their impact on patient prognosis using a cohort of ESOC patients treated at a single institution. Methods: Between March 2005 and October 2015, 355 ESOC patients treated with concurrent chemoradiotherapy were identified from a prospectively maintained and institutional-regulatory-board-approved clinical database. Dose-distribution parameters of the whole heart, the atria, the ventricles, the left main coronary artery, and three main coronary arteries were extracted for analysis. Results: Within a median follow-up time of 67 months, 14 patients experienced MCEs at a median of 16 months. The incidence of MCEs was significantly associated with the left anterior descending coronary artery (LAD) receiving ≥30 Gy (V30Gy) (p = 0.048). Patients receiving LAD V30Gy ≥ 10% of volume experienced a higher incidence of MCEs versus the LAD V30Gy < 10% group (p = 0.044). The relative rate of death increased with the left main coronary artery (LMA) mean dose (Gy) (p = 0.002). Furthermore, a mutual promotion effect of hyperlipidemia and RT on MCEs was observed. Conclusion: Radiation dose to coronary substructures is associated with MCEs and overall survival in patients with ESOC. In this study, the doses to these substructures appeared to be better predictors of toxicity outcomes than mean heart dose (MHD) or whole-heart V30Gy. These findings have implications for reducing coronary events through radiation therapy planning.
Open AccessThe Impact of Radiation Dose to Heart Substructures on Major Coronary Events and Patient Survival after Chemoradiation Therapy for Esophageal Cancer
Background: There is a paucity of data regarding the association between radiation exposure of heart substructures and the incidence of major coronary events (MCEs) in patients with esophageal cancer (ESOC) undergoing chemoradiation therapy. We studied radiation dosimetric determinants of MCE risk and measured their impact on patient prognosis using a cohort of ESOC patients treated at a single institution. Methods: Between March 2005 and October 2015, 355 ESOC patients treated with concurrent chemoradiotherapy were identified from a prospectively maintained and institutional-regulatory-board-approved clinical database. Dose-distribution parameters of the whole heart, the atria, the ventricles, the left main coronary artery, and three main coronary arteries were extracted for analysis. Results: Within a median follow-up time of 67 months, 14 patients experienced MCEs at a median of 16 months. The incidence of MCEs was significantly associated with the left anterior descending coronary artery (LAD) receiving ≥30 Gy (V30Gy) (p = 0.048). Patients receiving LAD V30Gy ≥ 10% of volume experienced a higher incidence of MCEs versus the LAD V30Gy < 10% group (p = 0.044). The relative rate of death increased with the left main coronary artery (LMA) mean dose (Gy) (p = 0.002). Furthermore, a mutual promotion effect of hyperlipidemia and RT on MCEs was observed. Conclusion: Radiation dose to coronary substructures is associated with MCEs and overall survival in patients with ESOC. In this study, the doses to these substructures appeared to be better predictors of toxicity outcomes than mean heart dose (MHD) or whole-heart V30Gy. These findings have implications for reducing coronary events through radiation therapy planning.